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Introduction
The reporting of human randomized
controlled trials (RCTs) was improved
significantly by the introduction of the
CONSORT (Consolidated Standards of
Reporting Trials) statement in 1996 [1].
CONSORT also led to improvements in
the overall quality of human RCTs, bene-
fitting trial design, accounting of subjects,
and rigour of data analysis [2,3]. Whilst
human RCTs and whole animal studies
may have different objectives (e.g., defining
mechanisms versus demonstrating clinical
efficacy), the fundamental requirements for
generating reliable and unbiased data are
verysimilar,andthusstandards of reporting
should also be similar. The introduction of
the ARRIVE (Animal Research: Reporting
InVivoExperiments)guidelinesforconduct
and scientific reporting of animal studies in
2010 [4] represented a major step forward
in attempting to improve the quality of
performing and reporting animal-based
research in the same way that the CON-
SORT statement did for RCTs [1].
Here, we argue that whilst the ARRIVE
guidelines are a major step forward, the
standards of reporting animal experiments
still lag behind those of RCTs. As a result,
the validity of results from animal studies and
their interpretation are frequently in ques-
tion. We put forward a series of suggestions
for modifying the ARRIVE guidelines to
ensure that animal studies catch up. Wide-
spread adoption of these guidelines should
improve the overall quality of animal studies,
thus improving their relevance to humans.
Introduction to the CONSORT
and ARRIVE Guidelines
Well-designed and conducted human
RCTs are widely regarded as providing
the top level of scientific evidence for
health care interventions (National Health
and Medical Research Council of Austra-
lia, 2009). The CONSORT statement
provides guidelines for reporting the
design, conduct, analysis, and interpreta-
tion of RCTs and has been adopted by
over 400 journals and several key editorial
bodies. Its implementation has led to
marked improvements in the quality and
transparency of reporting of RCTs [2,3].
In contrast, the reporting of animal
studies received comparatively little atten-
tion until the publication of the ARRIVE
guidelines in 2010 [4]. These guidelines
were spurred by a survey of 271 studies
reporting original research on rats, mice,
and non-human primates carried out in the
United Kingdom and the United States of
America [5]. The results painted a poor
picture of the quality of reporting in animal
research. Only59% of the 271 articlesstated
the hypothesis or objective of the study, the
number of animals used, and characteristics
of the animals. Few of the papers surveyed
reported using random allocation to treat-
ment group (13%) or blinding of outcome
assessment (14%), and statistical methods
werenot described adequately in 30% of the
publications [5]. In a similar review of
animal studies published in Cancer Research,
only 28% reported random allocation of
animals to treatment groups, only 2%
reported blinding of observers to this
allocation, and none reported methods to
determine sample size [6]. Similar concerns
a b o u tu n d e r r e p o r t i n gc r u c i a la s p e c t so f
study design and conduct have been raised
by a recent (June 2012) U.S. National
Institute of Neurological Disorders and
Stroke workshop to ‘‘improve the reporting
of preclinical studies in grant applications
and publications’’ [7]. The authors of the
meeting report emphasized the probable
impact that the gap in standards of reporting
between animal studies and human clinical
trials has had on impairing effective trans-
lation from bench to clinic. For example,the
false positive rate resulting from poorly
performed or reported preclinical experi-
ments may explain why, of the .1,000
treatments investigated for neuroprotection
in stroke, none have proved effective
clinically [8].
Since 2010, the ARRIVE guidelines
have been reprinted by 11 high-impact
international journals, and close to 100
scientific journals now include the ARRI-
VE guidelines in their instructions to
authors [9]. The ARRIVE guidelines
follow the same general principles as the
CONSORT statement and reflect the
growing recognition of the need for
greater uniformity and accountability in
the conduct and reporting of animal-based
research, yet they fall short in key areas.
The core elements of both sets of
guidelines are presented in Table 1, and
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the key reporting elements for well-done
RCTs that are not yet included in the
ARRIVE guidelines. Specifically, we ar-
gue that there is a need for more explicit
instructions, particularly in relation to
reporting of randomization, blinding, and
sample size justification, to ensure that
these guidelines are properly implemented
and achieve the ultimate aim of improving
the design, conduct, and analysis of animal
studies, and therefore their usefulness.
Study Setting; Exclusion/
Inclusion Criteria
The CONSORT criteria require com-
plete descriptions of the study setting and
the eligibility criteria used to select the trial
participants [1]. These criteria are critical
to assess generalizability of the results.
Studies in which the source population is
restricted or the eligibility criteria are tight
are less likely to be generalizable to a wide
swath of patients and populations [10]. In
addition, volunteers for most RCTs tend
to be healthier than those who do not
choose to participate, and thus results may
not be generalizable to patients who are
less well.
These issues are just as relevant in
animal studies. Most animal experiments
are conducted on a single breed and
strain, which authors almost always report
(99% of the studies surveyed by Kilkenny)
[5]. However, other inclusion and exclu-
sion criteria, such as age, sex, weight/body
condition scores, and health status, are
often vague or unreported [5]. The
ARRIVE guidelines currently have mini-
mal requirements in this area (Table 1;
‘‘Participants’’). In addition, most animal
researchers have clear ideas about the
‘‘quality’’ of animals that they choose to
include, but they typically do not report
these quality criteria, how they apply
them, or how many animals they excluded
based on these criteria. In the same way
that RCTs often have a ‘‘volunteer bias,’’
results of animal experiments may not
apply even to the same age, sex, and strain
if the investigator chooses only the health-
iest animals on which to intervene.
Run-In Period
In RCTs that address efficacy, investi-
gators will often exclude otherwise eligible
participants who fail a run-in period (i.e., a
period to test their short-term ability to
adhere to the treatment regimen irrespec-
tive of group assignment). The purpose is
to maximize the number of participants
who take a ‘‘full dose’’ of intervention as
well as return for follow-up assessments
throughout the intervention period. Inves-
tigators often employ similar ‘‘run-in’’ or
acclimatization periods in animal studies,
most commonly to assess the response of
individual animals to a particular nutri-
tional regimen or surgical procedure.
However, even if authors refer to such
an acclimatization period, they rarely if
ever detail the number and characteristics
of animals who fail the run-in. Run-in, or
acclimatization, periods may increase the
internal validity of results, but they also
typically reduce generalizability.
Randomization
RCTs are distinguished from observa-
tional studies by the process of random
allocation to treatment group, which, if
done properly on an adequately large
sample, minimizes confounding. Con-
founding refers to the nuisance effect of a
third variable obscuring the true associa-
tion between exposure and outcome, and
it is the one inherent potential limitation of
all observational studies. Randomization
equalizes both measured and unmeasured
confounders across treatment groups, iso-
lating the experimental treatment as the
only difference between them.
Random Allocation
To be successful, random allocation
must be truly random, and most RCTs
now use a computer-generated random
sequence of numbers to assign treatment
status. In contrast, there is very little
emphasis randomization technique, or its
reporting, in animal research. None of the
271 animal-based papers reviewed by
Kilkenny provided adequate details of
the randomization procedure [5]. The
ARRIVE guidelines are not explicit in
requesting reporting of full details of
allocation method, including methods of
randomization (Table 1; ‘‘Randomiza-
tion’’). Adding this reporting requirement
is likely to encourage more robust alloca-
tion methods in animal studies, minimiz-
ing risk of confounding.
Reporting of Baseline Characteristics
Success of randomization can be veri-
fied by reporting a range of baseline
characteristics that could potentially con-
found the observed results, according to
treatment assignment [10]. Whilst the
majority of the studies surveyed by Kilk-
enny (2009) stated the sex (74%) and either
the age or weight (76%) of the animals
overall, these characteristics were not
broken down by treatment group [5].
Rarely, if ever, do animal experimenters
report anything but a few specific baseline
characteristics by treatment group. The
ARRIVE guidelines call for reporting
baseline data but do not specify reporting
according to treatment assignment, which
is necessary to assess the success of
randomization.
Blinding (Masking)
As reflected in CONSORT, the partic-
ipants and all personnel who perform
assessments in an RCT should be unaware
of treatment assignment [1,10]. Blind-
ing—whether on the part of participant
or staff—helps to ensure that measured
treatment response is not affected by
conscious or unconscious bias, or any
other factor unrelated to the biological
action of the treatment. It is preferable for
RCT participants to be blinded to the
hypothesis of the study, for the same
reasons. In addition, in most RCTs,
investigators do not unmask the treatment
assignment until the experiment is com-
plete, so as not to bias data collection or
analysis during the study period.
Kilkenny’s 2009 survey reported that
86% of animal studies did not include any
report of blinding [5]. While blinding of
participants is certainly not as pertinent in
animal experiments as in RCTs, blinding
of data assessors to treatment assignment
is. Even so-called objective measures, such
as weight and blood pressure, are subject
to systematically inaccurate observation
[11]. Many animal studies employ a small
team, often involving postgraduate stu-
dents or junior postdoctoral staff who are
responsible for treatment administration,
assessment of outcomes, and analysis of
data. Having intervention staff also per-
form outcome assessments and analyse
data is contrary to best practice and is
likely to increase bias. Thus, we suggest
that ARRIVE guidelines (Table 1) call for
authors to report how personnel who
performed randomization, collected and
cleaned data, and analysed results were
blinded to treatment allocation, thereby
encouraging researchers to follow this
critical practice.
Attrition
In almost all RCTs, the number with
outcome assessments is lower than the
number randomized [10]. This loss to
follow-up, or attrition, can have a number
of causes, including inability of the re-
search team to contact participants or to
carry out particular assessments. Attrition
rates of more than 20% are generally
cause for concern, as large loss to follow-
up can introduce selection bias. Accurately
PLOS Biology | www.plosbiology.org 2 February 2013 | Volume 11 | Issue 2 | e1001481Table 1. Comparison of the CONSORT and ARRIVE guidelines.
Element CONSORT ARRIVE
Introduction
Background and objectives Scientific background and explanation of rationale (2a) Include sufficient scientific background (including
relevant references to previous work) to understand the
motivation and context for the study, and explain the
experimental approach and rationale (3a)
Explain how and why the animal species and model
being used can address the scientific objectives and,
where appropriate, the study’s relevance to human
biology (3b)
Specific objectives or hypotheses (2b) Clearly describe the primary and any secondary
objectives of the study, or specific hypotheses being
tested (4)
Methods
Description of study design Description of trial design (such as parallel, factorial) including
allocation ratio (3a)
Indicate number of experimental and control groups
(6a); provide precise details of all procedures carried out
(7); provide rationale for methods (7d)
Describe changes to methods after trial commencement (3b) Describe any modifications to reduce adverse events (16)
Participants Description of eligibility criteria (4a) Provide further relevant information such as the source
of animals, international strain nomenclature, genetic
modification status (e.g., knock-out), genotype, etc. (8b)
Settings and location of data collection (4b) State when and where data were collected (7b and c);
provide details of housing, husbandry conditions (9a and
b)
Interventions The interventions for each group with sufficient details to allow
replication, including how and when they were actually
administered (5)
For each experiment and each experimental group,
including controls, provide precise details of all
procedures carried out (7)
Outcomes Completely defined prespecified primary and secondary outcome
measures, including how and when they were assessed (6a)
Clearly define the primary and secondary experimental
outcomes assessed (e.g., cell death, molecular markers,
behavioural changes) (12)
Any changes to trial outcomes after the trial commenced, with
reasons (6b)
Not specified
Sample size How sample size was determined (7a) Explain how number of animals was arrived at (10b)
When applicable, explanation of any interim analyses and stopping
guidelines (7b)
Not specified
Randomization
Sequence generation Method used to generate the random allocation sequence (8a) Not specified
Type of randomization, including any restriction (blocking or
block size) (8b)
Give full details of how animals were allocated to
experimental groups, including randomization or
matching if done (11a); describe the order in which the
animals in the different experimental groups were
treated and assessed (11b)
Allocation concealment
mechanism
Mechanism used to implement random allocation sequence
(details of steps taken to conceal allocation) (9)
Any steps taken to minimise the effects of subjective
bias when allocating animals to treatment (e.g.,
randomization procedure) and when assessing results
(e.g., if done, describe who was blinded and when) (6b)
Implementation Who generated random number sequence, who enrolled
participants, who assigned participants to treatments (10)
Not specified
Blinding Who was blinded after assignment to interventions (11a) Any steps taken to minimise the effects of subjective
bias when assessing results (e.g., if done, describe who
was blinded and when) (6b)
Analysis
Statistical methods Statistical methods used to compare groups for primary and
secondary outcomes (12a)
Provide details of statistical methods used for each
analysis (13a); specify the unit of analysis for each dataset
(13b); describe any methods used to assess whether the
data met the assumptions of the statistical approach
(13c)
Methods for additional analyses, such as subgroup analyses and
adjusted analyses (12b)
Not specified
Attrition For each group, the numbers of participants who were randomly
assigned, received intended treatment, and were analysed for the
primary outcome–flow diagram recommended (13a)
Specify numbers of animals used for each experiment
and number in each experimental group (10a); indicate
the number of independent replications of each
experiment, if relevant (10c)
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pants through the study, from randomiza-
tion through data collection, is a key
element of the CONSORT statement
[1,12]. A key principle of RCTs is ‘‘once
in, always in.’’ Intent-to-treat analysis
follows this principle and is the corner-
stone of data analysis of RCTs. The
inverse is also true: an investigator cannot
replace a participant who died or is
otherwise lost to follow-up with a new
participant.
In animal studies attrition is also com-
mon. Kilkenny reported that only 198 of
the 271 papers reported animal numbers in
both the Methods and Results sections.
Importantly, of these 198 papers, 69 (35%)
either failed to report clearly the number of
animals enrolled and followed up or
reported different animal numbers in the
results from those inthe methods [5]. In the
majority of discrepant cases, numbers in
the Results section exceeded those in the
Methods section, without any explanation
from the authors. The ARRIVE guidelines
currently advise reporting numbers of
animals and reasons for exclusion at
baseline. We suggest the guidelines be
strengthened to include the number of
animals in each group at outcome assess-
ment aswell, the reasonsfor any attritionor
missing data elements, and as in RCTs, a
comparison of baseline characteristics in
animals followed to the end of the study
versus those who dropped out.
Authors should follow the same guide-
lines for each separate analysis, including
method (random allocation?) of selection
of animals for subgroup comparisons. A
flow-chart that details progress of animals
through the experiment(s) would improve
the transparency of reporting and aid
interpretation. Analogous to the RCT,
animal experiments should hew to the
intent-to-treat principle in data analyses,
and any revised ARRIVE guidelines
should include a requirement for authors
to report how they achieved this goal.
Adverse Events
The reporting of adverse events is a
critical part of RCTs to ensure safety of
the intervention being tested [1]. Likewise
in animal experiments, animal welfare is a
key concern, and adverse events may tip
the balance of benefit and risk for the
intervention being tested. A serious ad-
verse event may influence further studies
on the same intervention; a serendipitous
finding may open a whole new avenue of
research. ARRIVE guidelines advise re-
porting of details of adverse events,
representing a step forward in recognising
the importance of this information [4]. As
in human RCTs, animal investigators
should design protocols and instruments
to detect adverse events with the same
rigor as beneficial events. However, any
unexpected outcomes associated with a
treatment (whether adverse or not) should
also be reported.
Sample Size Issues
In RCTs, calculating the sample size a
priori ensures sufficient statistical power.
The calculation is based on an arbitrary
alpha level (usually 0.05), a clinically
important or detectable difference in
outcome between the treatment arms,
and the expected variance if the outcome
is a continuous variable. Typical targets
for power are 80% (or 90%)—that is, a
sample size large enough such that there is
no more than a 20% (or 10%) probability
that the study will fail to detect an effect
when one truly exists [10]. Sample size
justification before the RCT begins is an
important element of CONSORT
(Table 1). It is also important to recognize
that once data are collected, the confi-
dence interval provides the needed infor-
mation on precision of estimates. Power
calculations are for study planning, confi-
dence intervals for study reporting [13].
In contrast to RCTs, authors of animal
studies rarely report how they arrived at
the number of animals in the study and
typically do not report confidence inter-
vals. None of the papers included in
Kilkenny’s review provided any details of
sample size calculations [5]. Fortunately,
the ARRIVE guidelines require research-
ers to ‘‘explain how the number of animals
was arrived at’’ [4]. However, we believe
that these guidelines should go further and
stipulate that investigators report how they
determined the sample size a priori. The
alternative, adding animals until ‘‘statisti-
cal significance’’ appears, is usually a
highly biased approach as it violates
principles of random allocation and blind-
ing. We also believe that animal research-
ers should report confidence intervals in
addition to (or instead of) p values. The
most important results in any study are the
effect estimate and its precision. Whether
Table 1. Cont.
Element CONSORT ARRIVE
For each group, losses and exclusions after randomization,
together with reasons (13b)
If not all animals were included, explain why (15b)
Baseline data Table showing baseline demographic and clinical characteristics
of each group (15)
Provide details of the animals used, including species,
strain, sex, developmental stage, and weight (8a); report-
relevant characteristics and health status of animals prior
to treatment or testing (14)
Numbers analysed For each group, number of participants (denominator) included
in each analysis and whether the analysis was by original assigned
groups (16)
Report number of animals in each group included in
each analysis (15a)
Outcomes and estimation For each primary and secondary outcome, results for each group,
and the estimated effect size and its precision (such as 95%
confidence interval) (17a)
Report the results for each analysis carried out, with a
measure of precision (e.g., standard error or confidence
interval) (16)
For binary outcomes, presentation of both absolute and relative
effect sizes is recommended (17b)
Not specified
Ancillary analyses Results of any other analyses performed, including subgroup
analyses and adjusted analyses, distinguishing prespecified
from exploratory (18)
Not specified
Harms Harms: all important harms or unintended effects in each group (19) Give details of adverse events in each group (17a)
doi:10.1371/journal.pbio.1001481.t001
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such as 0.05 is unimportant [14].
Missing Data
Most clinical studies contain some
missing data on participants because
investigators were unable to collect a piece
of information or they excluded outlying
(‘‘erroneous’’) data points. Identifying er-
roneous values involves setting rigorous
criteria, ideally a priori. Criteria may
include a range of acceptability for a
particular variable, based on prior knowl-
edge of the normal range within the
population. If researchers set the range
before data collection, then they have the
opportunity to repeat the measurement if
it falls outside the range, thus minimizing
outliers in the final data set.
After data collection, the process
involves reviewing and excluding indi-
vidual data points based on biological
plausibility and/or agreement with val-
ues from other participants [10]. Inves-
tigators should apply predefined rules
during the data-cleaning phase, high-
lighting outlying values and enabling
decisions (blinded to treatment group)
on whether specific data points are
erroneous. It may be possible to verify
some data queries by reviewing the
source data or, in the case of RCTs,
by contacting the participant.
In animal studies these processes should
be the same, except that no analogy to
contacting participants exists. Animal ex-
perimentalists rarely set a priori criteria for
reasonable ranges for outcome measures,
even though it is entirely possible. More-
over, data cleaning is most commonly
performed by individuals who are not
blinded to the treatment group. Reviewing
potentially erroneous data in a blinded
manner is crucial. ARRIVE should re-
quire researchers to report the procedures
for exclusion of data points, including
whether blinded to treatment assignment.
There is also a need to develop
guidelines for animal studies to handle
missing values, which have the same
potential to produce systematic bias as
does attrition. In RCTs and observational
studies of humans, multiple imputation is
gaining favour.
Conclusions and
Recommendations: Building on
the ARRIVE Guidelines
In biomedical science, clinical and
animal studies must be of high quality to
yield valid inferences regarding aetiology,
pathophysiology, prevention, and treat-
ment. Whole animal experiments and
RCTs work hand-in-hand to achieve these
goals. Animal studies have the ability to
unravel biological mechanisms and to
suggest potential intervention strategies,
whilst RCTs establish the efficacy of
interventions on clinical outcomes and
can provide invaluable evidence to estab-
lish aetiology. It stands to reason that both
should adhere to the same rigor in study
design and analysis.
In comparison with RCTs, however,
the design and reporting of animal studies
has received relatively little attention from
the scientific community and thus has
lagged in quality. The 2010 ARRIVE
guidelines are an important first step
toward transparency in reporting of ani-
mal studies, thus providing an incentive
for researchers to improve their methods.
Conducting follow-up surveys of animal
studies, similar to those undertaken fol-
lowing the introduction of the CON-
SORT statement, will be important to
gauge the effectiveness of ARRIVE in
improving the quality of conduct and
reporting of animal studies.
In addition, some areas of the ARRI-
VE guidelines need improvement, which
we suggest should mirror the evolution
Table 2. Suggested modifications to the ARRIVE guidelines.
Subsection Suggested Additions
Methods
Participants/experimental animals (a) Provide clear details of eligibility criteria in relation to strain, weight range, age range, etc. in Methods section
of manuscript; (b) provide description of any run-in testing of suitability of animals for the main experiment; (c)
clearly define primary and secondary outcome measures.
Sample size (a) Provide justification of sample size selection and whether this was determined a priori (based on prespecified
primary outcome).
Randomization
Randomization sequence generation (a) Report details of method of generating randomization sequence, including details of stratification if used.
Allocation concealment mechanism (a) Provide details of whether the persons generating the randomization schedule were blinded to treatment.
Blinding (a) Provide details of whether persons carrying out randomization, data collection, and data analysis were unaware
of treatment group allocation/study hypothesis.
Statistical methods (a) Indicate any subgroup analysis undertaken and details of how animals came to be included in the subgroup; b.
report methods of accounting for non-independence of subjects (e.g. litter mates); c. Indicate whether intent-to-
treat analysis was used.
Results
Attrition a. Provide a flow-chart of animals from source population through first allocation to the study, assignment to
treatment group, to completion of experiment for each outcome measure; (b) provide description of criteria used
for exclusion of animals/data points from analysis and whether these were determined a priori; (c) provide
explanations for discrepancies in numbers between experiments/outcome measures (attrition, missing data); (d)
provide explanation of process for reviewing erroneous data and whether this was undertaken blinded to
treatment group.
Baseline data Provide details of the animals used, including species, strain, sex, developmental stage, and weight for each
experimental group (preferably in tabular form).
Numbers analysed (a) Report number of animals in each group included in each analysis and whether this was by original assigned
groups.
doi:10.1371/journal.pbio.1001481.t002
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SORT. We have made specific recom-
mendations in the areas of reporting of
inclusion/exclusion criteria, randomiza-
tion, blinding, adverse/unexpected
events, sample size, and missing data
(summarized in Table 2). We also
believe that a registry of animal exper-
iments would reduce publication bias, as
do sites such as www.clinicaltrials.gov
for human RCTs. Such steps are inte-
gral to improving the usefulness of whole
animal experiments.
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